| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for I7G from our risk checks.
Ipsen S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €115.00 |
| 52 Week High | €129.70 |
| 52 Week Low | €100.30 |
| Beta | 0.64 |
| 1 Month Change | 9.00% |
| 3 Month Change | 8.59% |
| 1 Year Change | 3.42% |
| 3 Year Change | 42.79% |
| 5 Year Change | 14.66% |
| Change since IPO | 422.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| I7G | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.6% | 0.9% | -1.0% |
| 1Y | 3.4% | -27.7% | 2.0% |
Return vs Industry: I7G exceeded the German Pharmaceuticals industry which returned -27.9% over the past year.
Return vs Market: I7G matched the German Market which returned 2.5% over the past year.
Price Volatility
| I7G volatility | |
|---|---|
| I7G Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: I7G has not had significant price volatility in the past 3 months.
Volatility Over Time: I7G's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 5,325 | David Loew | www.ipsen.com |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Ipsen S.A. Fundamentals Summary
| I7G fundamental statistics | |
|---|---|
| Market cap | €9.46b |
| Earnings (TTM) | €617.10m |
| Revenue (TTM) | €3.31b |
15.3x
P/E Ratio2.9x
P/S RatioIs I7G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I7G income statement (TTM) | |
|---|---|
| Revenue | €3.31b |
| Cost of Revenue | €571.20m |
| Gross Profit | €2.74b |
| Other Expenses | €2.12b |
| Earnings | €617.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 7.47 |
| Gross Margin | 82.72% |
| Net Profit Margin | 18.66% |
| Debt/Equity Ratio | 9.6% |
How did I7G perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield16%
Payout RatioDoes I7G pay a reliable dividends?
See I7G dividend history and benchmarks| Ipsen dividend dates | |
|---|---|
| Ex Dividend Date | May 30 2024 |
| Dividend Pay Date | Jun 03 2024 |
| Days until Ex dividend | 26 days |
| Days until Dividend pay date | 30 days |
Does I7G pay a reliable dividends?
See I7G dividend history and benchmarks